The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Update on the diagnosis and treatment of Pneumocystis pneumonia
Open accessAbstract
Pneumocystis is an opportunistic fungal pathogen that causes an often-lethal pneumonia in immunocompromised hosts. Although the organism was discovered in the early 1900s, the first cases of Pneumocystis pneumonia in humans were initially recognized in Central Europe after the Second World War in premature and malnourished infants. This unusual lung infection was known as plasma cellular interstitial pneumonitis of the newborn, and was characterized by severe respiratory distress and cyanosis with little or no fever and no pathognomic physical signs. At that time, only anecdotal cases were reported in adults and usually these patients had a baseline malignancy that led to a malnourished state. In the 1960–1970s additional cases were described in adults and children with hematological malignancies, but Pneumocystis pneumonia was still considered a rare disease. However, in the 1980s, with the onset of the HIV epidemic, Pneumocystis prevalence increased dramatically and became widely recognized as an opportunistic infection that caused potentially life-treating pneumonia in patients with impaired immunity. During this time period, prophylaxis against this organism was more generally instituted in high-risk patients. In the 1990s, with widespread use of prophylaxis and the initiation of highly active antiretroviral therapy (HAART) in the treatment of HIV-infected patients, the number of cases in this specific population decreased. However, Pneumocystis pneumonia still remains an important cause of severe pneumonia in patients with HIV infection and is still considered a principal AIDS-defining illness. Despite the decreased number of cases among HIV-infected patients over the past decade, Pneumocystis pneumonia continues to be a serious problem in immunodeficient patients with other immunosuppressive conditions. This is mostly due to increased use of immunosuppressive medications to treat patients with autoimmune diseases, following bone marrow and solid organ transplantation, and in patients with hematological and solid malignancies. Patients with hematologic disorders and solid organ and hematopoietic stem cell transplantation are currently the most vulnerable groups at risk for developing this infection. However, any patient with an impaired immunity, such as those receiving moderate doses of oral steroids for greater than 4 weeks or those receiving other immunosuppressive medications are at also at significant risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhuang, H., & Alavi, A. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.29278 · Cited by 524 · cited 2×
“(FDG-PET) and Ga-67 scintigraphy have been reported as potential tools to assist in the early diagnosis of Pneumocystis pneumonia [Zhuang and Alavi, 2002; Tumeh et al. 1992].”
MethodHelweg-Larsen, J., Benfield, T. L., Eugen-Olsen, J., Lundgren, J. D., & Lundgren, B. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03320-6 · Cited by 274 · cited 1×
“Isolated cases of treatment and prophylaxis failure have been associated with such mutations [Hauser et al. 2001; Helweg-Larsen et al. 1999].”
BackgroundDihydropteroate Synthase Gene Mutations in Pneumocystis and Sulfa Resistance
Huang, L., Crothers, K., Atzori, C., Benfield, T., Miller, R., Rabodonirina, M., & Helweg-Larsen, J. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1010.030994 · Cited by 131 · cited 1×
“Several studies have revealed mutations in the DPHS gene, the target for TMP and pyrimethamine, as well as the genes products that are targeted by SMX and dapsone [Crothers et al. 2005; Huang et al. 2004; Nahimana et al. 2004].”
Background
Cited by
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Onishi, A., Sugiyama, D., Kogata, Y., Saegusa, J., Sugimoto, T., Kawano, S., Morinobu, A., Nishimura, K., & Kumagai, S. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.05267-11 · Cited by 328
Tasaka, S., & Tokuda, H. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0453-0 · Cited by 123
Recent Advances in the Diagnosis of Pneumocystis Pneumonia
Song, Y., Ren, Y., Wang, X., & Li, R. (2016) · Medical Mycology Journal · doi:10.3314/mmj.16-00019 · Cited by 29
Diagnosis and Management of Pneumocystis Pneumonia in Resource-poor Settings
Oladele, R. O., Otu, A. A., Richardson, M. D., & Denning, D. W. (2018) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2018.0010 · Cited by 23
Metadata
- Authors
- Carmona, E. M., & Limper, A. H.
- Venue
- Therapeutic Advances in Respiratory Disease
- Publisher
- SAGE Publications
- Published
- 2010-08-24
- Volume
- 5
- Issue
- 1
- Pages
- 41-59
- ISSN
- 1753-4658 (ISSN-L)
- 1753-4666
- OpenAlex
- W1999350359
- Cited by
- 174
- References
- 3
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.